Incyte’s product portfolio
Incyte’s (INCY) product portfolio includes drugs for oncology as well as non-oncology. For oncology, the product portfolio includes targeted therapies as well as immunotherapies. However, products marketed by Incyte include only Jakafi and Iclusig.
Another product, baricitinib, is under pivotal studies for the treatment of rheumatoid arthritis.
The above chart shows the present status of drugs under development by Incyte. As we already saw, Jakafi is licensed to Novartis (NVS) for marketing outside the United States. Novartis markets Jakafi as Jakavi.
Worldwide rights for capmatinib are licensed to Novartis, while worldwide rights for baricitinib are licensed to Eli Lilly (LLY).
Incyte has classified its oncology product portfolio into two categories based on the method of treatment used to cure the disease. These categories are as follows:
- targeted anti-cancer therapies
- immuno-oncology or immunotherapies
Targeted anti-cancer therapies include drugs that target cancer cells but cause less damage to normal cells. Jakafi and capmatinib are targeted therapy drugs in Incyte’s portfolio. You can read more details about Jakafi in the previous parts of this series.
In June 2016, Incyte presented data from its Phase I and Phase II studies of capmatinib at the annual meeting of the American Society of Clinical Oncology.
Immunotherapies target a patient’s immune system to fight cancer cells. Epacadostat is an immunotherapy drug in Incyte’s portfolio.
Incyte also added Iclusig (ponatinib) to its portfolio after acquiring rights for the drug from Ariad Pharmaceuticals (ARIA) in June 2016. It’s approved for the treatment of chronic myeloid leukemia as well as Philadelphia chromosome-positive acute lymphoblastic leukemia for patients who cannot be treated with other tyrosine kinase inhibitors. Iclusig competes with Bristol-Myers Squibb’s (BMY) Sprycel, Pfizer’s (PFE) Bosulif, and Novartis’s (NVS) Tasigna and Gleevec.
Non-oncology drugs include baricitinib and ruxolitinib. Baricitinib is licensed to Eli Lilly.
Incyte will receive milestone payments from Eli Lilly for baricitinib after the drug is approved. Then Incyte will receive royalties. AbbVie’s (ABBV) Humira is also used for the treatment of rheumatoid arthritis.
Incyte announced an agreement with Eli Lilly for the development and commercialization of ruxolitinib for the treatment of graft-versus-host disease in US markets. It entered into another agreement with Novartis for development and commercialization rights for ruxolitinib outside the United States. The registration process for ruxolitinib in US markets will be initiated in the second half of 2016.
Investors can consider ETFs such as the PowerShares Dynamic Biotech & Genome ETF (PBE), which holds ~5.1% of its total assets in Incyte.